Roka will price IPO of 5 million shares between $14.00 and $16.00

BofA, Leerink are joint bookrunners; Cowen and Wedbush will assist

By Devika Patel

Knoxville, Tenn., July 7 – Roka BioScience, Inc. will sell 5 million common shares in its initial public offering with a 30-day greenshoe of 750,000 additional shares, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The deal was announced May 21.

The shares will be sold at a price expected to fall between $14.00 and $16.00 per share.

BofA Merrill Lynch and Leerink Partners are the joint bookrunning managers. Cowen and Co. and Wedbush PacGrow Life Sciences are the co-managers.

Proceeds will be used for research and development.

The molecular diagnostics company is based in Warren, N.J. The company intends to list its common stock on the Nasdaq under the symbol “ROKA.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.